Table 1 Selected completed immunotherapy trials in pretreated, advanced NSCLC
From: The next generation of immunotherapy: keeping lung cancer in check
Trial name | Phase | Histology | Therapy | mOS | 1-year OS (%) | DOR | mPFS | 1-year PFS (%) | mORR (%) | Ref |
|---|---|---|---|---|---|---|---|---|---|---|
CheckMate 017 | 3 | SQ | NIVO | 9.2 | 42 | NR | 3.5 | 21 | 20 | [9] |
DOC | 6 | 24 | 8.4 | 2.8 | 6 | 9 | Â | |||
CheckMate 057 | 3 | NONSQ | NIVO | 12.2 | 50.5 | 17.1 | NR | 18.5 | 19.2 | [10] |
DOC | 9.4 | 39 | 5.6 | NR | 8.1 | 12.4 | Â | |||
KEYNOTE-010 | 2/3 | ALL | PEMBRO 2 (PD-L1+) | 9.4 (14.9) | NR | NR | 3.9 | NR | NR | [12] |
PEMBRO 10 (PD-L1+) | 10.8 (17.3) | NR | NR | 4 | NR | NR | Â | |||
DOC | 8.6 (8.2) | NR | NR | 4 | NR | NR | Â | |||
POPLAR | 2 | ALL | ATEZO | 12.6 | NR | NR | 4.2 | NR | 17 | [13] |
DOC | 9.7 | NR | NR | NR | NR | NR | Â | |||
OAK | 3 | ALL | ATEZO | 13.8 | 55 | 16.3 | 2.8 | NR | 14 | [15] |
DOC | 9.6 | 41 | 6.2 | 4.0 | NR | 13 | Â | |||
KEYNOTE-021 | 1/2 | ALL | PEMBRO + IPI | 17 | NR | 14 | 6 | NR | 24 | [17] |